.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Fuji
Mallinckrodt
Colorcon
McKinsey
US Army
Daiichi Sankyo
QuintilesIMS
AstraZeneca

Generated: November 24, 2017

DrugPatentWatch Database Preview

Patents Expiring in February 2031

« Back to Dashboard
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY PALLIATIVE TREATMENT OF PROSTATE CANCER
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-002Apr 28, 2017RXYesYes► Subscribe► SubscribeY
Ariad
ALUNBRIG
brigatinib
TABLET;ORAL208772-001Apr 28, 2017RXYesNo► Subscribe► SubscribeY
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Cerexa
TEFLARO
ceftaroline fosamil
POWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeY METHOD OF TREATING BACTERIAL INFECTIONS
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► Subscribe DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► SubscribeYY
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► SubscribeYY
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Healthtrust
Cipla
Moodys
US Department of Justice
Baxter
Mallinckrodt
Chubb
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot